The Evaluation of Gemcitabine (Gemzar®) in Resistant and Relapsing Multiple Myeloma, Phase II

All stages multiple myeloma (MM); protein criteria must be present. Patients with IgM peaks or no quantifiable monoclonal proteins are ineligible. Patients must have received at least one prior treatment regimen for MM (chemo., biologic, RT and/or both) and shown indications of disease progression. If prior extensive RT, at least 21 days must have elapsed; if prior palliative RT, at least 14 days must have elapsed; PS 0 to 2; must have no plans for concomitant RT, hormonal or other chemo., while on protocol.